Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 95Terminated 24Recruiting 22Active not recruiting 22Unknown 11Withdrawn 10Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sexual Dysfunctions, Psychological 1Prostatic Neoplasms 1HER2-positive Breast Cancer 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Androgen Antagonists 10darolutamide 6Magnetic Resonance Spectroscopy 6apalutamide 5Docetaxel 5enzalutamide 4Specimen Handling 4Radiotherapy 4Radiosurgery 4Abiraterone Acetate 4Electroacupuncture 3Brachytherapy 3pembrolizumab 2bicalutamide 2Standard of Care 2Resistance Training 2Radiation 2Prednisone 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × Leuprolide × Clear all
NCT07444983 2026-03-03

Rezvilutamide for High-Risk Prostate Cancer After Surgery

Fujian Medical University Union Hospital

Phase NA Not yet recruiting
33 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡